Medindia

X

PRA International Expands Presence in Asia:

Saturday, September 19, 2009 General News J E 4
Advertisement
RALEIGH, N.C., July 15 PRA International, a leading Clinical Research Organization, announces the opening of its office in South Korea, complementing the company's extensive network of Asian operations and partnerships. South Korea is widely regarded as the third most important pharmaceutical market in Asia and one of the most important Asian countries for clinical studies to support new drug registrations. China, Japan and South Korea have made a joint statement of cooperation on clinical research and Japan is now accepting South Korean clinical trial data for Japanese registration.

The government of South Korea has demonstrated its commitment to establishing the country as a key clinical research location in the Asian region through the formation of KoNECT, the South Korea National Enterprise for Clinical Trials. The increasing volume of multinational clinical research taking place across all trial phases is indicative of the organization's success. Pharmaceutical companies are attracted to the region by its many advantages, including:

PRA has been providing clinical trial management services in South Korea since 2005, mainly through local partnerships. "Increasing customer expectations and project needs have prompted us to establish a legal entity and a local team of clinical professionals," noted Edward Ian, Sr. Director of Clinical Operations, PRA - Asia Pacific. "We anticipate significant growth of our operations in South Korea in the next few years to conduct clinical studies across a wide array of therapeutic indications, including oncology, neurology, respiratory disorders, infectious diseases and cardiovascular, endocrinology and metabolic disorders."

PRA's Executive VP of Product Registration for Europe, Africa and Asia-Pacific, Susan Stansfield, also commented: "The addition of the South Korean office to our existing Asian network, together with our continuing plans for expansion across the Asian region, further enhances PRA International's position as a CRO gateway to the world's most dynamic and rapidly expanding clinical research environment."

About PRA International

PRA International is a global Clinical Research Organization providing services through all phases of clinical development. We perform studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.

Pharmaceutical Research Associates Korea Limited is located at:

-- Quality of clinical data -- Progressive and efficient regulatory and ethical systems, exemplified by 30-day Approval Clock for INDs and adherence to ICH-GCP -- Active engagement of world-class Investigators -- Highly educated and committed clinical research professionals (CRAs, Study Nurses, and Study site personnel) -- State-of-the-art trial facilities including 124 Korean FDA accredited sites and 12 regional clinical trial centers overseen by KoNECT -- Proximity to vast patient populations

SOURCE PRA International
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Local Non-Profit Announces Collaboration With the ...
S
CMS Selects TrailBlazer Health Enterprises to Admi...